Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of ESR 1150 CL in Healthy Males
NCT02183259Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 1998
- Primary completion
- Dec 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ESR-1150-CL in stress urinary incontinence (SUI) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the plasma drug concentration-time curve from time zero to infinity up to 16 hours, Maximum drug plasma concentration up to 16 hours and 4 more. Started Nov 1998; status: completed.
02
Drugs
ESR-1150-CL
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT02183259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183259.